Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044759 · ClinicalTrials.gov registry record · Phase 3
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00044759 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer.
The verdict
NCT00044759, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
Interventions
- DRUG Piperacillin/Tazobactam (Tazocin)
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044759
The ClinicalTrials.gov registry entry for NCT00044759 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Piperacillin/Tazobactam (Tazocin) is the first listed.
NCT00044759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044759 about?
NCT00044759 is a clinical study titled "Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma". To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
What is the current status of trial NCT00044759?
This trial is currently completed. It is a Phase 3 study. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00044759?
The interventions under investigation include: Piperacillin/Tazobactam (Tazocin) (DRUG).
Who is sponsoring clinical trial NCT00044759?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.